ArticleDiabetology & metabolic syndrome2025
Triglyceride-glucose index and cancer risk: a prospective cohort study in Taiwan.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Post-treatment triglyceride-glucose index as survival protective factors in patients with esophageal squamous cell carcinoma.World journal of clinical oncology · 2026Article
- Association between the composite CRP-TyG index and incident malignancy risk in hospitalized patients with diabetes: a retrospective cohort study with nonlinear effect analysis.Frontiers in oncology · 2026Article
- Comprehensive evaluation of the prevalent insulin resistance indices for pan-cancer incidence and mortality prediction.Tropical medicine and health · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundInsulin resistance (IR) is a key metabolic abnormality associated with adverse health outcomes, including increased cancer risk. The triglyceride-glucose (TyG) index, a validated surrogate marker of IR, has been linked to metabolic dysfunction; however, its association with cancer risk in large population-based cohorts remains unclear. This study aimed to evaluate the relationship between TyG index and cancer risk in Taiwanese population.
methodsWe analyzed 150,592 participants from the Taiwan Biobank, among whom 148,809 were linked to the Taiwan Cancer Registry (2011-2022) for cancer incidence tracking. Cancer risk was assessed across TyG quartiles over a median follow-up of 5.7 years (IQR: 3.4-7.6). Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models, adjusting for key covariates.
resultsHigher TyG index levels were associated with increased risks of digestive system cancer (adjusted HR [aHR]: 1.17, 95% CI: 1.05-1.29), colorectal cancer (aHR: 1.25, 95% CI: 1.08-1.44), and urinary tract cancer (aHR: 1.47, 95% CI: 1.18-1.85). While subgroup trends suggested numerically higher risks in males, individuals aged ≥ 50 years, and those with overweight or obesity for these cancer types, formal interaction tests did not support statistically significant effect modification in these groups. Significant interactions were observed for overall cancers by age (P < 0.001) and BMI (P = 0.012), and for urinary tract cancer by drinking status (P = 0.047). In a subset of 19,808 participants with follow-up data, higher TyG quartiles were also linked to fatty liver, carotid plaques, and persistent IR over time (r = 0.75).
conclusionsHigher TyG index levels, indicative of greater IR, are associated with an elevated risk of digestive system, colorectal, and urinary tract cancers. Evaluating TyG index levels could assist in risk stratification for these cancers among individuals with persistent IR, supporting targeted prevention strategies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.